recombinant universal type i ifn-alpha  (PBL Assay)

Journal: Cell Communication and Signaling : CCS

Article Title: Epstein–Barr virus tegument protein BGLF2 in exosomes released from virus-producing cells facilitates de novo infection

doi: 10.1186/s12964-022-00902-7

Figure Lengend Snippet: Exosomal BGLF2 enhances the infectivity of EBV. A and B Akata(-) cells were infected with wildtype ( A ) and BGLF2-KO EBV ( B ) in the presence of BGLF2-containing exosomes. After 2 days, GFP positivity was determined by FACS. Results are presented as the mean ± SE of at least three independent experiments and as the relative infectivity to control treatment with PBS (infectivity value of 1). Double asterisks, p < 0.01; n.s., not significant. C The workflow of sample collection for RNA-seq/qRT-PCR analyses. Akata(-) cells were pretreated with exosomes for 16 h, and then infected with BGLF2-KO EBV. The infected cells were collected via FACS at 24 hpi. Total RNA extracted from the sorted cells was subjected to RNA-seq and qRT-PCR. D Read counts of EBV genes in BGLF2-KO EBV-infected cells that were treated with BGLF2-containing or control exosomes by RNA-seq. E Gene expression levels were normalized as counts per million followed by log 2 -transformation with a pseudo-count of 1. Each bar indicates the log 2 fold change of a viral gene expression between treatment with exosomes with or without BGLF2. Viral gene expression kinetics are categorized into five groups: latent, immediate early, early, leaky late, and late . F Validation of enhanced EBV gene expression by qPCR. Data are presented as the mean ± SE. Samples were tested in duplicate. Asterisk, p < 0.05; double asterisks, p < 0.01; n.s., not significant. G DAVID analysis of RNA-seq data from BGLF2-KO EBV-positive cells treated with BGLF2-containing or control exosomes. FDR, false discovery rate. H HEK293 cells were treated with BGLF2-containing exosomes for 16 h. Cells were challenged with transfection of poly(I:C) (2 μg/ml) for 2.5 h. RT-qPCR was conducted. Data are presented as the mean ± SE of three independent experiments. Asterisk, p < 0.05; n.s., not significant. H Exosomal BGLF2 inhibited type I IFN signaling. AGS/EBV-EGFP cells were pretreated with exosomes for 16 h, and then infected with or without IFN alpha (1000 Unit/mL) for 1 h. Lysates were analyzed by immunoblotting using the indicated antibodies. BGLF2-HA was detected using the anti-HA antibody. J Type I IFN inhibited EBV infection. Akata(-) cells were infected with EBV-EGFP in the presence of IFN alpha and beta (100 or 500 Unit/mL). After 2 days, GFP positivity was determined by FACS. Results are presented as the mean ± SE of three independent experiments. Double asterisks, p < 0.01; n.s., not significant

Article Snippet: Recombinant human type I IFN alpha (Cat# 11200-1) and IFN beta (Cat# 11415-1) were purchased from PBL Assay Science (Piscataway, NJ, USA).

Techniques: Infection, Control, RNA Sequencing, Quantitative RT-PCR, Gene Expression, Transformation Assay, Biomarker Discovery, Transfection, Western Blot

Journal: iScience

Article Title: IL-27 induces IFN/STAT1-dependent genes and enhances function of TIGIT + HIVGag-specific T cells

doi: 10.1016/j.isci.2021.103588

Figure Lengend Snippet:

Article Snippet: Recombinant human IFN-Alpha , pbl Assay Science , Cat# 11200-2.

Techniques: Control, Recombinant, Staining, Electron Microscopy, Software, Enzyme-linked Immunosorbent Assay

Journal: Cell Reports

Article Title: Sarbecovirus ORF6 proteins hamper induction of interferon signaling

doi: 10.1016/j.celrep.2021.108916

Figure Lengend Snippet:

Article Snippet: Recombinant IFN-α , PBL Assay Science , Cat# 11200-2.

Techniques: Virus, Recombinant, Modification, Reverse Transcription, SYBR Green Assay, Protease Inhibitor, Luciferase, Magnetic Beads, Plasmid Preparation, Quantitative RT-PCR, Software